Core Viewpoint - The stock of HeFu China (SH603122) has experienced significant volatility, with a cumulative increase of 256.29% over 14 trading days, leading to a temporary suspension of trading to protect investors' interests [1][5]. Trading Performance - HeFu China achieved 12 out of 14 trading days with a closing price at the daily limit, with a total trading volume of 8.859 million hands and a total transaction value of 13.48 billion yuan, resulting in a turnover rate of 222.56% [5]. - During the same period, the relevant sector's performance was only a 14.11% increase, while the overall market index saw a decline of 0.16% [5]. Financial Performance - In Q3 2025, HeFu China reported a net profit attributable to shareholders of approximately -5.05 million yuan, a year-on-year decline of 225.26%, primarily due to changes in the domestic macroeconomic environment and price reductions in the medical industry [12]. - The company's revenue for the reporting period was 181.2 million yuan, down 21.27% year-on-year, and the total profit was -5.44 million yuan, a decrease of 193.80% [14]. Market Valuation - As of November 14, 2025, HeFu China's static price-to-earnings (P/E) ratio was 343.67, significantly higher than the industry average of 30.94, indicating a potential overvaluation of the stock [14]. - The company has warned that its stock price has deviated significantly from its fundamentals, suggesting that investors may face considerable risks if the stock continues to rise abnormally [11][15]. Company Background - HeFu China, established in October 2000 and listed on the Shanghai Stock Exchange in February 2022, has built long-term cooperative relationships with over 1,000 domestic and international manufacturers and agents [15]. - The company provides a wide range of in vitro diagnostic products and consumables, with nearly 37,000 items offered to hospitals as of mid-2025 [15].

Core Viewpoint - The stock of HeFu China (SH603122) has experienced significant volatility, with a cumulative increase of 256.29% over 14 trading days, leading to a temporary suspension of trading to protect investors' interests [1][4]. Group 1: Stock Performance - HeFu China has recorded 12 out of 14 trading days with a closing price at the daily limit, with a total trading volume of 885.9 million shares and a turnover of 13.48 billion yuan, resulting in a turnover rate of 222.56% [4]. - The stock's performance significantly outpaced its industry, which saw a rise of only 14.11%, while the broader market (Shanghai Composite Index) declined by 0.16% during the same period [4]. Group 2: Trading Suspension - The company announced a trading suspension starting November 17, 2025, for a maximum of three trading days, following a request to the Shanghai Stock Exchange [1][3]. - The stock will resume trading after the disclosure of a verification announcement [1]. Group 3: Financial Performance - For Q3 2025, HeFu China reported a net profit attributable to shareholders of approximately -5.05 million yuan, a decline of 225.26% year-on-year, primarily due to changes in the macroeconomic environment and price reductions in the medical industry [9][10]. - The company's revenue for the reporting period was 181.2 million yuan, down 21.27% compared to the previous year, with a total profit of -5.44 million yuan, reflecting a decrease of 193.80% [10]. Group 4: Valuation Concerns - As of November 14, 2025, HeFu China's price-to-earnings (P/E) ratio stood at 343.67, significantly higher than the industry average of 30.94, indicating potential overvaluation [11]. - The company has warned investors about the risks associated with its stock price, which has deviated significantly from its fundamentals [9][11].